Century Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 28.06 million compared to USD 31.26 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.53 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.87 USD | +11.24% |
|
+27.23% | -14.16% |
Jun. 18 | Century Therapeutics Proposes Secondary Offering of 7.87 Million Shares | MT |
Jun. 17 | Piper Sandler Adjusts Price Target on Century Therapeutics to $12 From $9, Maintains Overweight Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.16% | 218M | |
+24.27% | 47.07B | |
+46.79% | 42.06B | |
-3.39% | 39.98B | |
+37.40% | 33.02B | |
-7.79% | 27.9B | |
+18.58% | 27.63B | |
+48.35% | 14.37B | |
+44.38% | 13.45B | |
+0.95% | 12.03B |
- Stock Market
- Equities
- IPSC Stock
- News Century Therapeutics, Inc.
- Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024